SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is experiencing a strong momentum-driven rally fueled by optimism over upcoming Full Self-Driving software updates and potential production milestones, leading to heavy options activity. While the community is sharply divided between bullish traders chasing the breakout and skeptical bears citing concerns over high valuations and technical overextension, the stock remains a high-beta focal point for those looking to capitalize on aggressive market volatility.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack in the Box is trending due to a wave of speculative interest surrounding a potential short squeeze, fueled by its high short interest and relatively low float. While some community members view the stock as a long-term turnaround play, others are actively debating the company's debt levels and its recent decision to sell its Del Taco subsidiary.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is rallying on strong investor optimism driven by reports that a Rakuten-led consortium, which includes ASTS, has been selected for Japan's billion-dollar J-LEO satellite contract. The community is actively discussing this potential catalyst as a significant validation of their direct-to-device technology, fueling a short squeeze as investors bet on the companys competitive positioning against other space sector players.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is surging as the company capitalizes on unprecedented defense demand and a substantial, multi-billion dollar backlog, while investors closely monitor the integration of its recent acquisitions. Community sentiment remains split between excitement over the company's long-term leadership in autonomous drone technology and heated debate regarding its forward-looking guidance and recent operational restructuring.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is seeing massive upward momentum driven by intense short interest and mounting anticipation for an imminent phase 3 trial milestone, leading the community to discuss a potential gamma squeeze and long-term buyout scenarios. Investors are actively tracking high borrow fees and record engagement, with many pointing to the trial's unusually long duration as evidence of strong clinical outcomes.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors react to a major strategic partnership with Tolmar to commercialize its Alpha DaRT therapy for prostate cancer. The community is highly bullish, emphasizing the platform's recent clinical successes and the significant de-risking represented by this commercial runway, while many view the current price action as a strategic buying opportunity for long-term holders.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is generating significant buzz as the community anticipates the launch of the Goliath blockchain mainnet, with active discussions focusing on potential institutional partnerships and broader ecosystem upgrades. Traders are closely monitoring the technical charts for a breakout, though sentiment remains polarized between long-term holders accumulating for utility and skeptics wary of historical price volatility and project transparency.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is currently drawing significant community attention as shareholders look ahead to a July 29th Advisory Committee meeting and an August 22nd PDUFA date for Deramiocel. Investors are intensely debating the regulatory implications of the upcoming AdCom, with many bullishly interpreting it as a path to a broader label approval while others monitor the volatility surrounding the FDA's current review process and the ongoing legal dispute with Nippon Shinyaku.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is trending after reports of a raid on its Taiwan offices by local authorities, which investors fear signals an escalation in an ongoing probe into the alleged smuggling of restricted high-end chips to China. While some community members dismiss the news as a recycled nothing-burger and a bear-trap for retail investors, many others are expressing deep concern over repeated regulatory scandals and lack of transparency, fueling intense debate between those buying the dip and those urging a full exit due to perceived management failure.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as the market reacts to a newly announced Bitcoin monetization program that grants the company flexibility to sell portions of its holdings to fund share buybacks and dividends, sparking debate over whether this shift improves financial sustainability or undermines its core 'HODL' narrative. Community discussions are heavily divided, with some bulls interpreting the move as a strategic liquidity play to defend the stock and support preferred securities, while vocal bears argue the company is executing a 'buy high, sell low' cycle that signals fundamental distress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud

Shareholders of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) saw the stock plunged roughly 50% on June 1, 2026, following disclosure of an FDA safety concerns related to the PRC2 inhibitor drug class. Those who lost money on FULC are encouraged tosubmit their information immediately. You may also...

What's Going On With Fulcrum Therapeutics Stock On Thursday?

Fulcrum Therapeutics halts pociredir development after FDA concerns over malignancy risk and begins a strategic review.read more...

FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End

Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.

FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations

FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations PR Newswire NEW YORK, June 3, 2026 SEC filings reflected...

Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? 

Equity

The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology. 


Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) PR...

FULC Stock Crashes After Hours: What Investors Need To Know

Fulcrum Therapeutics stock plunged after the company discontinued its lead sickle cell disease drug following FDA concerns.read more...

FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk 

Fulcrum discontinued development of its lead candidate, pociredir, for sickle cell disease. 


After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Fulcrum Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.23	--	--	N/A
Q1 '26	-$0.29	-$0.25	15.04%	BEAT
Q4 '25	-$0.30	-$0.31	-3.65%	MISSED
Q3 '25	-$0.29	-$0.31	-5.53%	MISSED
Q2 '25	-$0.29	-$0.28	3.45%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

FULCFulcrum Therapeutics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest FULC News